Boston Imaging, the United States headquarters of Samsung’s digital radiography (DR) and ultrasound business, today announced that Samsung has signed a supply contract with Lunit, a provider of artificial intelligence (AI) powered solutions for cancer diagnostics and therapeutics, to enable faster and more accurate chest screenings for timely interventions with improved patient outcomes.
The Lunit INSIGHT CXR, an AI-powered chest X-ray analysis solution, and Lunit Insight CXR Triage, an FDA 510(k)-cleared AI triage solution for critical chest findings, will enable Samsung’s CAD (Computer Aided Detection) AI to help radiologists manage a higher volume of patient exams by prioritizing those with suspected abnormalities.
Over the past two years, Samsung has made significant investments to bring best-in-class technology to radiology leaders and administration ensuring more enhanced patient care and workflow efficiency while maintaining a low-dose imaging experience.
The Lunit AI solution software is commercially available on Samsung digital radiology products as of Q1 2024. As part of the collaboration with Lunit, Samsung will continue to expand on validating the AI solution to detect the 10 most common abnormalities in chest X-ray including nodule, pneumothorax, atelectasis, cardiomegaly, calcification, consolidation, pleural effusion, pneumoperitoneum, mediastinal widening, fibrosis and support tuberculosis screening.
Samsung will offer the upgraded systems to North America and European markets and to the Middle East, South America and Southeast Asia.
